ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Methods: The relative complementary DNA (cDN...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiyong, Zhu, Xiaoli, Zhang, Hongming, Fan, Xiaobo, Xue, Xiulei, Chen, Yan, Ding, Chenbo, Zhao, Jianwen, Wu, Guoqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604217/
https://www.ncbi.nlm.nih.gov/pubmed/28928874
http://dx.doi.org/10.7150/jca.19897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604217/
https://www.ncbi.nlm.nih.gov/pubmed/28928874
http://dx.doi.org/10.7150/jca.19897

Ejemplares similares